News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

TAKE Solutions, Inc. Extends Safety & Pharmacovigilance Service Offerings with Launch of SafetyReady for Oracle Argus Safety Suite Customers



10/13/2011 12:45:51 PM

Princeton, NJ – Oct 13, 2011 – TAKE Solutions Ltd. [BSE: 532890 | NSE: TAKE], a leader in Life Sciences solutions development, today announced the extension of its Safety and Pharmacovigilance services with the launch of SafetyReady for Oracle customers. The solution helps accelerate implementation for life sciences organizations looking to jumpstart Safety & Pharmacovigilance adoption efforts and operations planning in as little as five weeks. For small to medium-sized businesses with limited resources and staff constraints, TAKE offers SafetyReady Cloud, an on-demand option that provides easy deployment and maintenance of critical applications. TAKE’s SafetyReady suite also includes SafetyReady Upgrade and SafetyReady Migrate, modules to ease upgrades and migration to Oracle Argus Safety Suite.

TAKE’s SafetyReady solution includes the capabilities to help customers implement Oracle’s industry leading integrated platform for end-to-end pharmacovigilance solutions, from clinical development to post-marketing surveillance, ensuring regulatory compliance and comprehensive product oversight. TAKE has leveraged the Safety & Pharmacovigilance functional expertise acquired through its subsidiary WCI Consulting, and has also developed tools and accelerators that will speed up the implementation process, reducing the cost while delivering quality.

“TAKE has been providing solutions and services to life sciences customers for over 10 years, and safety is one of our core areas of expertise," said Kishore Rachapudi, president & COO, TAKE Solutions. "SafetyReady allows customers to adopt an industry-leading, platform for adverse event management in a swift and cost-effective manner. SafetyReady leverages our domain experience in Safety to enable efficient handling of safety cases as well as regulatory compliance and reporting for customers."

TAKE Solutions is a Gold level member in Oracle PartnerNetwork (OPN). Learn more about TAKE Solutions’ Life Sciences business here.

About the Oracle PartnerNetwork

Oracle PartnerNetwork (OPN) Specialized is the latest version of Oracle's partner program that provides partners with tools to better develop, sell and implement Oracle solutions. OPN Specialized offers resources to train and support specialized knowledge of Oracle products and solutions and has evolved to recognize Oracle’s growing product portfolio, partner base and business opportunity. Key to the latest enhancements to OPN is the ability for partners to differentiate through Specializations. Specializations are achieved through competency development, business results, expertise and proven success. To find out more visit http://www.oracle.com/partners.

About TAKE Solutions

TAKE Solutions, Ltd. [BSE: 532890 | NSE: TAKE] is a leading global business technology company with domain expertise in Life Sciences (LS) and Supply Chain Management (SCM). TAKE provides cost-effective and comprehensive solutions for enterprises across diverse sectors including pharmaceuticals, high technology, consumer packaged goods, oil/gas, and automotive. TAKE’s SCM product suite includes distinct technology with embedded IP that spans enterprise mobility, trading partner collaboration, and material tracking. In the LS domain, TAKE offers IP-based software and extensive knowledge-based solutions to enable efficient clinical, regulatory, safety and commercialization processes.

TAKE has been recognized as a leader by IDC’s MarketScape Worldwide Life Sciences R&D IT Outsourcing for 2011. TAKE’s global headquarters is in Chennai, India; its U.S. headquarters is located in Princeton, New Jersey. TAKE has a proven track record as a trusted partner in delivering world-class solutions to more than 400 customers worldwide. For more information, please visit www.takesolutions.com.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES